Physician profile
Felipe Martinez
NPI 1922240449
$194,342.17
in general payments reported to CMS, 2019-2025
9 companies · $291 in 2025
The $291 reported for 2025 was more than what a typical Nuclear Medicine provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114K · 2020: $34K · 2021: $42K · 2022: $3,690 · 2023: $287 · 2024: $720 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,297.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $174,478.63 | 2019-2022 | |
| Genentech USA, INC. | $17,400.29 | 2019 | |
| Siemens Medical Solutions USA, INC. | $1,953.99 | 2019-2025 | Biograph Vision 600 (8 Ring/64 Ct), Biograph Horizon-3r |
| Progenics Pharmaceuticals, INC. | $247.86 | 2022-2025 | |
| Blue Earth Diagnostics | $123.64 | 2025 | Posluma |
| Bayer Healthcare Pharmaceuticals INC. | $76.34 | 2019 | |
| Ge Healthcare | $33.69 | 2021 | |
| United Therapeutics Corporation | $14.76 | 2019 | |
| Agfa Healthcare Corporation | $12.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felipe Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.